{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:22:27Z","timestamp":1778620947474,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep02640","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T09:02:47Z","timestamp":1378976567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects"],"prefix":"10.1038","volume":"3","author":[{"given":"Michael","family":"Prystowsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Willmott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Wasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Antkowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Loudig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Parish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"BFsrep02640_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 127, 2893\u20132917 (2010).","journal-title":"Int. J. Cancer."},{"key":"BFsrep02640_CR2","doi-asserted-by":"crossref","unstructured":"Jemal, A. et al. Global cancer statistics. CA: A Cancer Journal for Clinicians. 61, 69\u201390 (2011).","DOI":"10.3322\/caac.20107"},{"key":"BFsrep02640_CR3","doi-asserted-by":"crossref","unstructured":"Takes, R. et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Archives of Otolaryngology-Head & Neck Surgery. 412\u2013419 (1997).","DOI":"10.1001\/archotol.1997.01900040048008"},{"key":"BFsrep02640_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1046\/j.1471-4159.2003.01581.x","volume":"84","author":"A Boutillier","year":"2003","unstructured":"Boutillier, A., Trinh, E. & Loeffler, J. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 84, 814\u2013828 (2003).","journal-title":"J. Neurochem."},{"key":"BFsrep02640_CR5","doi-asserted-by":"publisher","first-page":"10826","DOI":"10.1128\/MCB.24.24.10826-10834.2004","volume":"24","author":"JH Patel","year":"2004","unstructured":"Patel, J. H. et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5\/PCAF and TIP60. Mol. Cell. Biol. 24, 10826\u201310834 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFsrep02640_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/sj.cdd.4401581","volume":"12","author":"S Roy","year":"2005","unstructured":"Roy, S., Packman, K., Jeffrey, R. & Tenniswood, M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 12, 482\u2013491 (2005).","journal-title":"Cell Death Differ."},{"key":"BFsrep02640_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-4020-6554-5_13","volume":"615","author":"S Shankar","year":"2008","unstructured":"Shankar, S. & Srivastava, R. K. Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer - HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 615, 261\u2013298 (2008).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFsrep02640_CR8","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","volume":"14","author":"L Ellis","year":"2008","unstructured":"Ellis, L. et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Can. Res. 14, 4500\u20134510 (2008).","journal-title":"Clin. Can. Res."},{"key":"BFsrep02640_CR9","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/leu.2009.182","volume":"23","author":"P Maiso","year":"2009","unstructured":"Maiso, P. et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia. 23, 2265\u20132274 (2009).","journal-title":"Leukemia."},{"key":"BFsrep02640_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","volume":"147","author":"M Dickinson","year":"2009","unstructured":"Dickinson, M. et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Brit. J. of Haematol. 147, 97\u2013101 (2009).","journal-title":"Brit. J. of Haematol."},{"key":"BFsrep02640_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2009.015495","volume":"95","author":"EM Ocio","year":"2010","unstructured":"Ocio, E. M. et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 95, 794\u2013803 (2010).","journal-title":"Haematologica."},{"issue":"3","key":"BFsrep02640_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.leukres.2010.06.026","volume":"35","author":"Eric Sanchez","year":"2011","unstructured":"Sanchez, E. et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leukemia Research. 35, 373\u2013379 (2011).","journal-title":"Leukemia Research"},{"key":"BFsrep02640_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/07357907.2011.590568","volume":"29","author":"JD Hainsworth","year":"2011","unstructured":"Hainsworth, J. D. et al. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 29, 451\u2013455 (2011).","journal-title":"Cancer Invest."},{"key":"BFsrep02640_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ijc.26057","volume":"130","author":"MG Catalano","year":"2011","unstructured":"Catalano, M. G. et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int. J. Cancer. 130, 694\u2013704 (2011).","journal-title":"Int. J. Cancer."},{"key":"BFsrep02640_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","volume":"8","author":"MC Crisanti","year":"2009","unstructured":"Crisanti, M. C. et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol. Cancer Ther. 8, 2221\u20132231 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"BFsrep02640_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","volume":"66","author":"D Rathkopf","year":"2010","unstructured":"Rathkopf, D. et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 66, 181\u2013189 (2010).","journal-title":"Cancer Chemother Pharmacol."},{"key":"BFsrep02640_CR17","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-10-2430","volume":"71","author":"MJ LaBonte","year":"2011","unstructured":"LaBonte, M. J. et al. The dual EGFR\/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 71, 3635\u20133648 (2011).","journal-title":"Cancer Res."},{"key":"BFsrep02640_CR18","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/ijc.25594","volume":"128","author":"BP Martin","year":"2010","unstructured":"Martin, B. P. et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int. J. Cancer. 128, 2735\u20132747 (2010).","journal-title":"Int. J. Cancer."},{"key":"BFsrep02640_CR19","first-page":"225","volume":"9","author":"SF Jones","year":"2011","unstructured":"Jones, S. F. et al. A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. Clin. Adv. Hematol. Oncol. 9, 225\u2013230 (2011).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"BFsrep02640_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/path.2554","volume":"218","author":"MB Prystowsky","year":"2009","unstructured":"Prystowsky, M. B. et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2\/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J. Pathol. 218, 467\u2013477 (2009).","journal-title":"J. Pathol."},{"key":"BFsrep02640_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.freeradbiomed.2010.11.011","volume":"50","author":"P Pettazzoni","year":"2011","unstructured":"Pettazzoni, P. et al. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic. Biol. Med. 50, 313\u2013322 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"BFsrep02640_CR22","doi-asserted-by":"publisher","first-page":"e14335","DOI":"10.1371\/journal.pone.0014335","volume":"5","author":"W Brazelle","year":"2010","unstructured":"Brazelle, W. et al. Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells. PLoS ONE. 5, e14335 (2010).","journal-title":"PLoS ONE."},{"key":"BFsrep02640_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/hed.20478","volume":"29","author":"CJ Lin","year":"2007","unstructured":"Lin, C. J. et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 29, 163\u2013188 (2007).","journal-title":"Head Neck."},{"key":"BFsrep02640_CR24","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","volume":"66","author":"P Maiso","year":"2006","unstructured":"Maiso, P. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 66, 5781\u20135789 (2006).","journal-title":"Cancer Res."},{"key":"BFsrep02640_CR25","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.cellsig.2011.06.016","volume":"23","author":"Y-C Lin","year":"2011","unstructured":"Lin, Y.-C., Sun, S. H. & Wang, F.-F. Suppression of Polo like kinase 1 (PLK1) by p21Waf1 mediates the p53-dependent prevention of caspase-independent mitotic death. Cell. Signal. 23, 1816\u20131823 (2011).","journal-title":"Cell. Signal."},{"key":"BFsrep02640_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4161\/cc.1.1.101","volume":"1","author":"H Zhu","year":"2002","unstructured":"Zhu, H., Chang, B.-D., Uchiumi, T. & Roninson, I. Identification of promoter elements responsible for transcriptional inhibition of Polo-like Kinase 1 and Topoisomerase II alpha genes by p21WAF1\/CIP1\/SDI1. Cell cycle. 1, 59\u201366 (2002).","journal-title":"Cell cycle."},{"key":"BFsrep02640_CR27","doi-asserted-by":"publisher","first-page":"G696","DOI":"10.1152\/ajpgi.00575.2004","volume":"289","author":"SY Archer","year":"2005","unstructured":"Archer, S. Y. et al. The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21\/WAF-1-dependent mechanism in human colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G696\u2013703 (2005).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"BFsrep02640_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1673-8527(08)60030-2","volume":"35","author":"M Tategu","year":"2008","unstructured":"Tategu, M. et al. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor. J. gen genom. 35, 215\u2013224 (2008).","journal-title":"J. gen genom."},{"key":"BFsrep02640_CR29","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1128\/MCB.06663-11","volume":"32","author":"Y Li","year":"2012","unstructured":"Li, Y. et al. Regulation of a novel androgen receptor target gene, cyclin B1, through androgen-dependent E2F family member switching. Mol Cell Biol. 32, 2454\u20132466 (2012).","journal-title":"Mol Cell Biol."},{"key":"BFsrep02640_CR30","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1182\/blood-2007-10-117762","volume":"111","author":"A Scuto","year":"2008","unstructured":"Scuto, A. et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 111, 5093\u20135100 (2008).","journal-title":"Blood."},{"issue":"15","key":"BFsrep02640_CR31","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","volume":"12","author":"F. Giles","year":"2006","unstructured":"Giles, F. et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deactylase inhibitor, in patients with refractory hematologic malignancies. Cancer Therapy: Clinical. 12, 4628\u20134635.","journal-title":"Clinical Cancer Research"},{"key":"BFsrep02640_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/sj.onc.1210779","volume":"27","author":"FE Stevens","year":"2008","unstructured":"Stevens, F. E., Beamish, H., Warrener, R. & Gabrielli, B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene. 27, 1345\u20131354 (2008).","journal-title":"Oncogene."},{"key":"BFsrep02640_CR33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.biocel.2007.03.001","volume":"39","author":"M Ocker","year":"2007","unstructured":"Ocker, M. & Schneider-Stock, R. Histone deacetylase inhibitors: Signalling towards p21cip1\/waf1. Int. J. Biochem. Cell Biol. 39, 1367\u20131374 (2007).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFsrep02640_CR34","first-page":"5997","volume":"52","author":"KD Somers","year":"1992","unstructured":"Somers, K. D. et al. Frequent p53 mutation in head and neck cancer. Cancer Res. 52, 5997\u20136000 (1992).","journal-title":"Cancer Res."},{"key":"BFsrep02640_CR35","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1038\/sj.onc.1204468","volume":"20","author":"P Campomenosi","year":"2001","unstructured":"Campomenosi, P. et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 20, 3573\u20133579 (2001).","journal-title":"Oncogene."},{"key":"BFsrep02640_CR36","doi-asserted-by":"publisher","first-page":"e54102","DOI":"10.1371\/journal.pone.0054102","volume":"8","author":"L Bellucci","year":"2013","unstructured":"Bellucci, L., Dalvai, M., Kocanova, S., Moutahir, F. & Bystricky, K. Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS One 8, e54102 (2013).","journal-title":"PLoS One"},{"key":"BFsrep02640_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9, 400\u2013414 (2009).","journal-title":"Nat Rev Cancer."},{"key":"BFsrep02640_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.devcel.2008.04.014","volume":"14","author":"M Petronczki","year":"2008","unstructured":"Petronczki, M., L\u00e9n\u00e1rt, P. & Peters, J.-M. Polo on the Rise\u2014from Mitotic Entry to Cytokinesis with Plk1. Devel. Cell. 14, 646\u2013659 (2008).","journal-title":"Devel. Cell."},{"key":"BFsrep02640_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4161\/cc.7.9.5711","volume":"7","author":"DV Soni","year":"2008","unstructured":"Soni, D. V., Sramkoski, R. M., Lam, M., Stefan, T. & Jacobberger, J. W. Cyclin B1 is rate limiting but not essential for mitotic entry and progression in mammalian somatic cells. Cell Cycle. 7, 1285\u20131300 (2008).","journal-title":"Cell Cycle."},{"key":"BFsrep02640_CR40","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1038\/sj.onc.1202923","volume":"18","author":"L Delavaine","year":"1999","unstructured":"Delavaine, L. & La Thangue, N. Control of E2F activity by p21(Waf1\/Cip1). Oncogene. 18, 5381\u20135392 (1999).","journal-title":"Oncogene."},{"key":"BFsrep02640_CR41","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/carcin\/bgp079","volume":"30","author":"YL Chung","year":"2009","unstructured":"Chung, Y. L., Lee, M. Y. & Pui, N. N. M. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 30, 1387\u20131397 (2009).","journal-title":"Carcinogenesis."},{"key":"BFsrep02640_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00411-011-0384-7","volume":"50","author":"AC Miller","year":"2011","unstructured":"Miller, A. C., Cohen, S., Stewart, M., Rivas, R. & Lison, P. Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys. 50, 585\u2013596 (2011).","journal-title":"Radiat Environ Biophys."},{"key":"BFsrep02640_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1667\/RR1245.1","volume":"169","author":"SL Brown","year":"2008","unstructured":"Brown, S. L., Kolozsvary, A., Liu, J., Ryu, S. & Kim, J. H. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat. Res. 169, 474\u2013478 (2008).","journal-title":"Radiat. Res."},{"key":"BFsrep02640_CR44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hed.21198","volume":"32","author":"JC Brenner","year":"2002","unstructured":"Brenner, J. C. et al. Genotyping of UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 32, 417\u2013426 (2002).","journal-title":"Head Neck."},{"key":"BFsrep02640_CR45","unstructured":"Edelstein, A., Amodaj, N., Hoover, K., Vale, R. & Stuurman, N. Current Protocols in Molecular Biology. Ausubel F. M., et al. editors. Hoboken, NJ, USA: John Wiley & Sons, Inc.; (2001)."},{"key":"BFsrep02640_CR46","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1038\/sj.emboj.7600459","volume":"23","author":"W Zhu","year":"2004","unstructured":"Zhu, W., Giangrande, P. & Nevins, J. E2Fs link the control of G1\/S and G2\/M transcription. EMBO J. 23, 4615\u20134626 (2004).","journal-title":"EMBO J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep02640","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep02640.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep02640.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:04:23Z","timestamp":1715979863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep02640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,12,20]]}},"alternative-id":["BFsrep02640"],"URL":"https:\/\/doi.org\/10.1038\/srep02640","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]},"assertion":[{"value":"22 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2640"}}